Evaluation of the Effectiveness of Sugammadex for Digoxin Intoxication: An Experimental Study
- 225 Downloads
Previous studies have shown that cyclodextrin group medicines bind to various drugs. The hypothesis of our study is to determine whether sugammadex could bind to digoxin and delay the cardiovascular toxicity of that drug. Twenty-eight sedated Wistar rats were infused with digoxin at 3 mg/h (0.25 mg/ml). Five minutes after the start of infusion, animals were treated with a bolus of either 16 mg/kg (Sgdx16), 100 mg/kg (Sgdx100), or 1000 mg/kg (Sgdx1000) sugammadex. The control group infusion did not contain sugammadex. Heart rate, electrocardiography, and respiratory rate were monitored. The primary endpoint was time to asystole. Digoxin infusion continued until the animals arrested. The time to asystole for the Sgdx1000 group was significantly longer compared to that for the control group (p < 0.05). The mean lethal dose of digoxin was 5.35 ± 2.06 mg/kg in the saline-treated rats. On the other hand, the mean lethal dose of digoxin was 8.54 ± 1.51 mg/kg in the sugammadex 1000 group (p < 0.05). The mean lethal dose of digoxin was significantly higher than control group (p < 0.05). We found that the 1000 mg/kg dose of sugammadex delayed digoxin cardiotoxicity in a rat model of digoxin toxicity. We conclude that further research must be conducted on the interaction between digoxin and sugammadex.
KeywordsCyclodextrin Digoxin Toxicity Sugammadex
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.See, I., Shehab, N., Kegler, S. R., Laskar, S. R., & Budnitz, D. S. (2014). Emergency department visits and hospitalizations for digoxin toxicity: United States, 2005 to 2010. Circulation: Heart Failure, 7(1), 28–34.Google Scholar
- 8.Maron, B. A., & Rocco, T. P. (2011). Pharmacotherapy of congestive heart failure. In L. S. Bruton (Ed.), Goodman & Gillman’s the pharmacological basis of therapeutics (12th ed., pp. 789–813). New York, USA: Mc Graw Hill Publication.Google Scholar
- 11.Leor, J., Goldbourt, U., Rabinowitz, B., Reicher-Reiss, H., Boyko, V., Kaplinsky, E., et al. (1995). Digoxin and increased mortality among patients recovering from acute myocardial infarction: Importance of digoxin dose. The SPRINT study group. Cardiovascular Drugs and Therapy, 9, 723–729.CrossRefPubMedGoogle Scholar
- 27.Tripathi, K. D. (2009). Cardiac glycosides and drugs for heart failure. Essentials of medical pharmacology (6th ed., pp. 493–507). Jaypee Brothers: New Delhi.Google Scholar